Hansoh Pharmaceutical Group Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG549581067
HKD
33.72
-0.38 (-1.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Sino Biopharmaceutical Ltd.
WuXi AppTec Co., Ltd.
China Medical System Holdings Ltd.
Sinopharm Group Co., Ltd.
China Resources Pharmaceutical Group Ltd.
Hygeia Healthcare Holdings Co., Ltd.
Hansoh Pharmaceutical Group Co., Ltd.
Innovent Biologics, Inc.
Akeso, Inc.
HUTCHMED (China) Ltd.
BeiGene Ltd.

Why is Hansoh Pharmaceutical Group Co., Ltd. ?

1
Poor long term growth as Operating profit has grown by an annual rate 10.26% of over the last 5 years
2
With ROE of 15.17%, it has a Very Expensive valuation with a 5.98 Price to Book Value
  • Over the past year, while the stock has generated a return of 31.21%, its profits have risen by 1.6% ; the PEG ratio of the company is 24
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hansoh Pharmaceutical Group Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Hansoh Pharmaceutical Group Co., Ltd.
31.21%
2.18
40.89%
Hang Seng Hong Kong
8.76%
0.45
19.63%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
9.75%
EBIT Growth (5y)
10.26%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.39
Tax Ratio
14.03%
Dividend Payout Ratio
42.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
59.55%
ROE (avg)
13.25%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
5.98
EV to EBIT
36.16
EV to EBITDA
33.31
EV to Capital Employed
39.39
EV to Sales
12.23
PEG Ratio
24.03
Dividend Yield
0.06%
ROCE (Latest)
108.92%
ROE (Latest)
15.17%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
OPERATING CASH FLOW(Y)

Highest at HKD 13,838.11 MM

CASH AND EQV(HY)

Highest at HKD 35,158.97 MM

DEBT-EQUITY RATIO (HY)

Lowest at -88.96 %

INVENTORY TURNOVER RATIO(HY)

Highest at 2.37 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.6 times

NET SALES(Q)

Highest at HKD 8,314.47 MM

-2What is not working for the Company
DIVIDEND PAYOUT RATIO(Y)

Lowest at 0%

DIVIDEND PER SHARE(HY)

Lowest at HKD 4.6

Here's what is working for Hansoh Pharmaceutical Group Co., Ltd.

Operating Cash Flow
Highest at HKD 13,838.11 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Net Sales
Highest at HKD 8,314.47 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Net Sales
At HKD 8,314.47 MM has Grown at 33.17%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Cash and Eqv
Highest at HKD 35,158.97 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -88.96 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio
Highest at 2.37 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 4.6 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Hansoh Pharmaceutical Group Co., Ltd.

Dividend per share
Lowest at HKD 4.6
in the last five years
MOJO Watch
Company is distributing lower dividend than previous years

DPS (HKD)

Dividend Payout Ratio
Lowest at 0%
in the last five years
MOJO Watch
Company is distributing lower proportion of profits generated as dividend

DPR (%)